rct
    2025
    High Quality

    Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease

    Unknown authors

    Published in Neurology

    Key Findings

    Nicotinamide did not significantly lower CSF phospho-tau or improve cognition versus placebo in early Alzheimer disease.

    Conclusions

    Well-designed null result for a popular supplement.

    Supplements Studied

    Nicotinamide did not significantly lower CSF phospho-tau or improve cognition compared with placebo in early Alzheimer disease.

    Vitamin B3
    Vitamin

    Nicotinamide did not significantly lower CSF phospho-tau or improve cognition versus placebo in early Alzheimer disease.

    Outcomes Measured

    Amyloid Plaque Prevention
    Primary

    Nicotinamide did not significantly lower CSF phospho-tau or improve cognition compared with placebo in early Alzheimer disease.

    Study Details

    Year:2025
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.